VALN - EU regulator starts rolling review of Valneva's COVID-19 vaccine

The European Union's (EU) drug regulator has started a rolling review of a new coronavirus vaccine made by French startup Valneva (NASDAQ:VALN). VALN shares up 2.5% premarket at $64.50. The review decision was based on preliminary studies that suggest the vaccine, VLA2001, triggers an antibody response against the coronavirus. EMA approval would add another vaccine to the EU’s armory against COVID-19 as the bloc ramps up administering booster shots and some countries are preparing to deliver shots of Pfizer’s vaccine to children ages 5 to 11. Last month, the European commission signed a deal with Valneva to buy up to 60M doses of VLA2001 vaccine over two years.

For further details see:

EU regulator starts rolling review of Valneva's COVID-19 vaccine